Pointe Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Pointe Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$631K	Sell	817 -29	-3%	-$22.2K	0.31%	69
2025 Q4	$653K	Buy	846 +127	+18%	+$86.2K	0.32%	65
2025 Q3	$404K	Buy	719 +194	+37%	+$110K	0.2%	110
2025 Q2	$276K	Buy	525 +6	+1%	+$3.35K	0.14%	129
2025 Q1	$329K	Sell	519 -9	-2%	-$6.19K	0.19%	114
2024 Q4	$376K	Buy	528 +187	+55%	+$157K	0.22%	110
2024 Q3	$358K	Buy	+341	New	+$379K	0.21%	112
2023 Q2	–	Sell	-132	Closed	-$108K	–	337
2023 Q1	$108K	Buy	+132	New	+$99.6K	0.08%	181
2022 Q2	–	Sell	-571	Closed	-$399K	–	153
2022 Q1	$399K	Buy	571 +14	+3%	+$8.86K	0.25%	100
2021 Q4	$352K	Buy	+557	New	+$342K	0.21%	113

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Pointe Capital Management's REGN Position: Q1 2026 in Review

Pointe Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 3.4% in Q1 2026, selling an estimated $22.2K and leaving 817 shares worth $631K. The position accounts for 0.31% of the portfolio, ranked #69.

Pointe Capital Management first reported a position in REGN in Q4 2021 and has held it in 10 quarters since. The position peaked at $653K in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Pointe Capital Management held 817 shares of Regeneron Pharmaceuticals worth $631K as of Q1 2026.
Pointe Capital Management sold 29 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $22.2K.
Regeneron Pharmaceuticals made up 0.31% of Pointe Capital Management's portfolio in Q1 2026, its #69 holding.
Pointe Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
Pointe Capital Management's Regeneron Pharmaceuticals position peaked at $653K in Q4 2025.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Pointe Capital Management's 13F filing for Q1 2026, filed 15 May 2026.